Furthermore, the specific mTORC1 inhibitor INK-128 abolished the osteoclast differentiation ability differences measured between ANLN overexpression and control HCC cells (Fig. 5F-H and Supplementary Fig. 6G & H). This evidence concerns the gene ANLN and hepatocellular carcinoma.